Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Aptorum Group Ltd Market Cap
The Aptorum Group Ltd (APM) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered APM. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for APM is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedAPM 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Aptorum Group Ltd to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on APM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of APM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Initiates | Oct 7, 2022 |
China Renaissance | Buy | $22 | Initiates | Apr 2, 2019 |
When did it IPO
N/A
Staff Count
3
Country
United Kingdom
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Chung Yuen Huen
Market Cap
$4.0M
In 2023, APM generated $431,378 in revenue, which was a decrease of -66.71% from the previous year. This can be seen as a signal that APM's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 30 Apr 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aptorum Group (Nasdaq: APM) reported its fiscal year 2023 financial results and provided corporate updates, focusing on unmet needs in oncology, autoimmune, and infectious diseases.
Why It Matters - Aptorum Group's financial results and corporate updates signal its progress in key therapeutic areas, affecting investor sentiment and potential stock performance.
Wed, 06 Mar 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - Aptorum (NASDAQ: APM) shares surged following a merger agreement with YOOV Group, resulting in YOOV shareholders owning 90% of the combined entity post-deal.
Why It Matters - Aptorum's merger with YOOV Group could significantly alter its market position, impacting share value and investor sentiment due to the major ownership shift post-merger.
Wed, 06 Mar 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - Aptorum (NASDAQ: APM) is experiencing a significant increase in market value due to a merger between its subsidiary and an AI platform, driven by AI interest and institutional investor support.
Why It Matters - Aptorum's merger with an AI platform boosts its market value, reflecting investor enthusiasm for AI and potential growth, indicating strong future performance and interest from institutional investors.
Wed, 06 Mar 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aptorum Group Limited and YOOV Group Holding Ltd. have announced a merger agreement, pending approval by Aptorum's shareholders.
Why It Matters - The merger could enhance Aptorum's market position and growth potential, impacting its stock value and investor sentiment. Successful integration may lead to increased revenue and innovation.
Fri, 22 Dec 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aptorum Group (NASDAQ: APM) reported financial results for H1 2023, emphasizing progress in their therapeutic programs targeting oncology, autoimmune, and infectious diseases.
Why It Matters - Aptorum Group's financial results and progress in therapeutic development indicate potential growth opportunities, influencing investor sentiment and stock performance in the biopharmaceutical sector.
Thu, 21 Dec 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aptorum Group Limited (Nasdaq: APM) held its annual general meeting on December 20, 2023, in London, where all Class I directors were re-elected.
Why It Matters - Re-election of Class I directors at Aptorum Group signals stability in leadership, which can enhance investor confidence and potentially influence stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
